INBX - Inhibrx Biosciences, Inc. logo

INBX

Inhibrx Biosciences, Inc.

Net 7.05%top 1%Rev 0.00%top 1%Net income grew 100% of years1Y
Hold

Inhibrx Biosciences, Inc. develops biologic therapeutics targeting life-threatening conditions, focusing on cancer and orphan diseases. Its pipeline includes therapeutic candidates like INBRX-109 for chondrosarcoma and INBRX-106 for various solid tumors.

โš•๏ธ Healthcare NASDAQ Listed 2024 $ USD
$1,000 invested 1 year ago โ†’$4,487today

Score Overview

1 Year
Scoreโ€”
Net Growth7.05%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth0.00%
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-107.71%
Net Trend50%
Net Income Consistencyโ€”
Rev Growth6x
Rev Trend50%
Revenue Consistencyโ€”

See the full market ranking โ†’

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 98.36โ€”
1 Year2025-08-12
$ 21.92348.72%
All Time2024-05-29
$ 11.668x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 1M-$ 130M$ 161M
2025$ 1M-$ 140M$ 124M
IPO2024$ 200K$ 1.68B$ 152M

Explore beyond INBX

You're looking at Inhibrx Biosciences, Inc.. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies